Miragen Therapeutics (NASDAQ: MGEN) and Biocept (NASDAQ:BIOC) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, profitability, valuation, risk and institutional ownership.


How to Become a New Pot Stock Millionaire

This table compares Miragen Therapeutics and Biocept’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Miragen Therapeutics -662.30% -63.57% -51.14%
Biocept -426.48% -374.92% -169.29%

Valuation and Earnings

This table compares Miragen Therapeutics and Biocept’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Miragen Therapeutics $4.00 million 50.08 -$26.51 million ($1.38) -4.81
Biocept $5.07 million 3.22 -$21.61 million ($0.79) -0.30

Biocept has higher revenue and earnings than Miragen Therapeutics. Miragen Therapeutics is trading at a lower price-to-earnings ratio than Biocept, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Miragen Therapeutics has a beta of 1.31, meaning that its share price is 31% more volatile than the S&P 500. Comparatively, Biocept has a beta of 1.77, meaning that its share price is 77% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and target prices for Miragen Therapeutics and Biocept, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Miragen Therapeutics 0 1 8 0 2.89
Biocept 0 0 2 0 3.00

Miragen Therapeutics presently has a consensus price target of $17.19, suggesting a potential upside of 158.85%. Biocept has a consensus price target of $1.25, suggesting a potential upside of 420.83%. Given Biocept’s stronger consensus rating and higher possible upside, analysts plainly believe Biocept is more favorable than Miragen Therapeutics.

Institutional and Insider Ownership

19.0% of Miragen Therapeutics shares are owned by institutional investors. Comparatively, 8.7% of Biocept shares are owned by institutional investors. 44.4% of Miragen Therapeutics shares are owned by insiders. Comparatively, 7.7% of Biocept shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.


Biocept beats Miragen Therapeutics on 7 of the 13 factors compared between the two stocks.

Miragen Therapeutics Company Profile

Signal Genetics, Inc. is a commercial stage, molecular genetic diagnostic company. The Company is focused on providing diagnostic services that help physicians to make decisions concerning the care of cancer patients. The Company’s diagnostic service is the Myeloma Prognostic Risk Signature (MyPRS) test. The MyPRS test is a microarray-based gene expression profile (GEP), assay that measures the expression level of specific genes and groups of genes that are designed to predict an individual’s long-term clinical outcome/prognosis, giving a basis for personalized treatment options. The Company’s MyPRS test provides a whole-genomic expression profile of a patient’s multiple myeloma (MM). The Company offers MyPRS test in its laboratory located in Little Rock, Arkansas. The Company is licensed to sell its test in all 50 states.

Biocept Company Profile

Biocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. The company's cancer assays provide information to oncologists and other physicians that enable them to select personalized treatment for their patients who have been diagnosed with cancer based on molecular drivers. It offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer, small cell lung cancer, gastric cancer, colorectal cancer, prostate cancer, and melanoma. The company sells its cancer diagnostic assays directly to oncologists and other physicians at private and group practices, hospitals, and cancer centers in the United States, as well as markets its clinical trial and research services to pharmaceutical and biopharmaceutical companies, and clinical research organizations. Biocept, Inc. was founded in 1997 and is headquartered in San Diego, California.

Receive News & Ratings for Miragen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Miragen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.